Arecor
Arecor enables biologics to be more stable; highly-concentrated; and durable to temperature. Arecor has a proprietary and patented technology platform for improving the stability of a range of therapeutic proteins including vaccines.
Dr Guy Hill
Crescendo Biologics
Crescendo has developed a novel antibody fragment platform which generates fully human VH products, the smallest antibody fragments, that mature in vivo in a transgenic mouse. The company has a highly experienced antibody drug discovery team and capability. Crescendo is using the platform to develop a portfolio of differentiated medicines, with an initial focus on novel topical products, and is identifying companies interested in partnering this platform during 2013.
Come and see us at booth #73
Mr Matthew Roe
Dr Mike Romanos
Glythera
Glythera Limited is a biotechnology company specializing in the development of enhanced protein/peptide therapeutics through the use of advanced glycosylation and conjugation technologies. Originally spun-out from the University of Bath, the Company relocated to the Newcastle-upon-Tyne INEX incubator facility in 2012, following investment from the IP Group and the Finance for Business North East Technology Fund. Gylthera's core technologies - Permalink and Permacarb - allow the selective and stable functionalization and glycosylation of biopharmaceuticals for improved stability, bioavailability and efficacy.
Come and see us at booth #73
Dr David Simpson
ICT Biosciences
ICT Biosciences is the business arm of the Institute of Cancer Therapeutics for the delivery of all research and business activity. The Institute of Cancer Therapeutics houses a multidisciplinary team of researchers in the field of drug design, synthesis, screening and pharmacology. Our purpose built institute is configured to integrate all the elements of the preclinical drug discovery process, in keeping with our mission to research and develop new treatments with a focus on cancer and other proliferative diseases.
Come and see us at booth #73
Mr Stuart Nelson
Phynova Group
Phynova is an innovative life sciences company based in Oxford with research facilities in China that uses a plant chemistry platform to develop patented actives for use in pharmaceuticals, nutraceuticals, and personal care products. Drug candidates and functional ingredients under development target post-operative ileus (POI), MRSA, hepatitis C, glucose control and hyperpigmentation and melanin production.
Come and see us at booth #73
Dr Ian Scoular
Sareum
Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.
SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR.
Come and see us at booth #73
Dr Tim Mitchell
